A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of valganciclovir (Valcyte) in patients experiencing chronic fatigue syndrome with elevated antibody titers against human herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 19 Aug 2013
At a glance
- Drugs Valganciclovir (Primary)
- Indications Chronic fatigue syndrome; Epstein-Barr virus infections; Herpesvirus infections
- Focus Therapeutic Use
- Acronyms EVOLVE
- 30 Aug 2007 Status changed from recruiting to in progress.
- 25 Jul 2007 New trial record.